Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2020

View Archived Issues

Linking two liver cancer culprits

Functional analysis complements sequencing

Cerevance presents phase Ib data on CVN-058 for schizophrenia cognition

Lundbeck identifies new Kv3.1 potassium channel activators

Designed Cells, Chungbuk National University patent stem cell-derived exosome-rich culture medium

New phenothiazine derivative antibacterials discovered at the University of Copenhagen

Osaka University presents new histone demethylase inhibitors

New alpha-2B adrenoceptor antagonists described by Bayer

First-in-human PK data presented for ZM-H1505R, a novel HBV capsid assembly modulator

Positive 12-month data for AAV-RPGR in X-linked retinitis pigmentosa

Ependymomas may respond to PARP inhibitors

Biological E's novel COVID-19 subunit vaccine candidate enters phase I/II development

First-in-human interim results of ALN-AGT01 in patients with hypertension

Kangpu opens phase Ib/IIa study to evaluate KPG-818 in SLE

Inovio opens phase II segment of phase II/III study evaluating COVID-19 vaccine candidate INO-4800

Artelo receives clearance for phase I/II trial of ART-27.13 in cancer anorexia

FDA clears IND application for phase II study of NT-I7 plus atezolizumab in NSCLC

Phase III trial shows efficacy and safety of intravenous immunoglobulin in treating dermatomyositis

Innovent presents phase I data on IBI-302 for neovascular AMD

Bispecific 4-1BBx5T4 antibody ALG.APV-527 advancing towards clinic

IBI-188 does not show single-agent activity in phase I study, warrants further combination studies

Tofacitinib demonstrates long-term safety and efficacy in refractory dermatomyositis

FDA clears initiation of phase II trials of NBTXR-3 in HNSCC

TrippBio reports viral clearance in trial of TD-213 for mild to moderate COVID-19

HMGXB4 correlates with vascular inflammation and SMC phenotypic switching

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...